Wedbush Reiterates Outperform Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research note issued on Monday,RTT News reports. They currently have a $36.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 275.78% from the stock’s current price.

Several other brokerages also recently commented on KURA. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Wall Street Zen upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 26th. Finally, JMP Securities restated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Kura Oncology Stock Performance

Shares of NASDAQ KURA opened at $9.58 on Monday. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $8.52 and its two-hundred day moving average is $6.95. The company has a market cap of $831.52 million, a P/E ratio of -4.24 and a beta of 0.32. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $19.73.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The business had revenue of $15.29 million during the quarter, compared to the consensus estimate of $64.95 million. On average, equities analysts expect that Kura Oncology will post -2.44 EPS for the current year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 12,314 shares of the company’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $110,087.16. Following the sale, the insider directly owned 158,439 shares in the company, valued at $1,416,444.66. This represents a 7.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Kathleen Ford sold 6,892 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $61,614.48. Following the completion of the sale, the chief operating officer owned 63,375 shares in the company, valued at $566,572.50. This trade represents a 9.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 78,058 shares of company stock valued at $697,839. 6.40% of the stock is owned by insiders.

Institutional Trading of Kura Oncology

A number of large investors have recently bought and sold shares of KURA. Allspring Global Investments Holdings LLC acquired a new position in Kura Oncology in the third quarter worth $176,000. Merit Financial Group LLC acquired a new position in Kura Oncology in the third quarter worth $89,000. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in Kura Oncology by 22.0% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 69,300 shares of the company’s stock worth $613,000 after purchasing an additional 12,500 shares in the last quarter. CWM LLC boosted its stake in Kura Oncology by 185.9% in the third quarter. CWM LLC now owns 118,363 shares of the company’s stock worth $1,048,000 after purchasing an additional 76,957 shares in the last quarter. Finally, Brighton Jones LLC acquired a new position in Kura Oncology in the third quarter worth $108,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.